Celldex Announces Upcoming Late Breaking Oral Presentation Of 12 Week Results From Barzolvolimab Phase 2 Study In Chronic Inducible Urticaria At ACAAI 2024
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics will present 12-week results from its Phase 2 study of barzolvolimab for chronic inducible urticaria at the ACAAI 2024 meeting.
October 25, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics is set to present 12-week results from its Phase 2 study of barzolvolimab for chronic inducible urticaria at the ACAAI 2024 meeting. This could positively impact the stock if results are favorable.
The announcement of a late-breaking presentation at a major scientific meeting suggests that the results are significant. If the data is positive, it could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100